615 related articles for article (PubMed ID: 31076057)
21. New treatments for asthma: From the pathogenic role of prostaglandin D
Pelaia C; Crimi C; Vatrella A; Busceti MT; Gaudio A; Garofalo E; Bruni A; Terracciano R; Pelaia G
Pharmacol Res; 2020 May; 155():104490. PubMed ID: 31682916
[TBL] [Abstract][Full Text] [Related]
22. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
Domingo C
Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
[TBL] [Abstract][Full Text] [Related]
23. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants.
Gyles SL; Xue L; Townsend ER; Wettey F; Pettipher R
Immunology; 2006 Nov; 119(3):362-8. PubMed ID: 17067313
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
Pettipher R; Vinall SL; Xue L; Speight G; Townsend ER; Gazi L; Whelan CJ; Armer RE; Payton MA; Hunter MG
J Pharmacol Exp Ther; 2012 Feb; 340(2):473-82. PubMed ID: 22106101
[TBL] [Abstract][Full Text] [Related]
25. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
Peters MC; Wenzel SE
Lancet; 2020 Feb; 395(10221):371-383. PubMed ID: 32007172
[TBL] [Abstract][Full Text] [Related]
26. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
27. T2 Biologics for Chronic Obstructive Pulmonary Disease.
Yousuf A; Ibrahim W; Greening NJ; Brightling CE
J Allergy Clin Immunol Pract; 2019; 7(5):1405-1416. PubMed ID: 31076058
[TBL] [Abstract][Full Text] [Related]
28. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
[TBL] [Abstract][Full Text] [Related]
29. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
30. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
31. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
32. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
33. Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.
Santus P; Radovanovic D
Expert Opin Investig Drugs; 2016 Sep; 25(9):1083-92. PubMed ID: 27409410
[TBL] [Abstract][Full Text] [Related]
34. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
35. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
37. Biologic targeted therapy in allergic asthma.
Bice JB; Leechawengwongs E; Montanaro A
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):108-15. PubMed ID: 24468249
[TBL] [Abstract][Full Text] [Related]
38. Childhood asthma as an allergic disease: rationale for the development of future treatment.
Tang ML; Powell CV
Eur J Pediatr; 2001 Dec; 160(12):696-704. PubMed ID: 11795676
[TBL] [Abstract][Full Text] [Related]
39. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
40. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
